The Clinical Burden of Biliary Disease: A Global Perspective

  • Kirsten Muri BobergEmail author


Many biliary disorders are considered rare diseases (diseases affecting less than 50 per 100,000 inhabitants) according to the definition by the European Commission for Public Health. They still impose a burden on the patients affected and the health-care system. Although adequate population-based epidemiological studies on biliary diseases are scarce from several parts of the world, it is evident that there is a marked geographical variation in the incidence and prevalence rates of many of the conditions (Table 1.1). These observations are attributed to differences in the worldwide distribution of risk factors. Biliary diseases may be diagnosed in all age groups, even in the neonate. The disorders range from benign conditions with potential curative options, including liver transplantation, to devastating biliary tract cancers with very poor survival. Hopefully, ongoing efforts to elucidate the pathogenesis and define potential targets for therapy for biliary disorders will reduce the burden of these conditions in the future.


Primary Sclerosing Cholangitis Gallbladder Cancer Biliary Atresia Gallbladder Carcinoma Autoimmune Pancreatitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Kelly D. Pediatric cholestatic syndromes. In: Boyer TD, Manns MP, Sanyal AJ, editors. Zakim and Boyer’s hepatology: a textbook of liver disease. 6th ed. Philadelphia: Elsevier Saunders; 2012. p. 1223–56.CrossRefGoogle Scholar
  2. 2.
    Tiao MM, Tsai SS, Kuo HW, Chen CL, Yang CY. Epidemiological features of biliary atresia in Taiwan, a national study 1996-2003. J Gastroenterol Hepatol. 2008;23(1):62–6.PubMedGoogle Scholar
  3. 3.
    Hirschfield GM. Genetic determinants of cholestasis. Clin Liver Dis. 2013;17(2):147–59.CrossRefPubMedGoogle Scholar
  4. 4.
    Zollner G, Trauner M. Mechanisms of cholestasis. Clin Liver Dis. 2008;12(1):1–26.Google Scholar
  5. 5.
    Jacquemin E. Progressive familial intrahepatic cholestasis. Clin Res Hepatol Gastroenterol. 2012;36(Suppl 1):S26–35.CrossRefPubMedGoogle Scholar
  6. 6.
    Bjornsson ES, Jonasson JG. Drug-induced cholestasis. Clin Liver Dis. 2013;17(2):191–209.CrossRefPubMedGoogle Scholar
  7. 7.
    Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015;148(7):1340–52.Google Scholar
  8. 8.
    Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36(2):451–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K, Garcia-Ruiz E, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2):512–21.CrossRefPubMedGoogle Scholar
  10. 10.
    Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144(7):1419–25.Google Scholar
  11. 11.
    Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med. 2005;353(12):1261–73.CrossRefPubMedGoogle Scholar
  12. 12.
    Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary biliary cirrhosis. Hepatology. 2009;50(1):291–308.CrossRefPubMedGoogle Scholar
  13. 13.
    Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. Lancet. 2015;386:1565–75.CrossRefPubMedGoogle Scholar
  14. 14.
    Trivedi PJ, Lammers WJ, van Buuren HR, Pares A, Floreani A, Janssen HL, et al. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut. 2016;65:321–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012;56(5):1181–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Metcalf JV, Bhopal RS, Gray J, Howel D, James OF. Incidence and prevalence of primary biliary cirrhosis in the city of Newcastle upon Tyne. England Int J Epidemiol. 1997;26(4):830–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Kim WR, Lindor KD, Locke III GR, Therneau TM, Homburger HA, Batts KP, et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology. 2000;119(6):1631–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Boonstra K, Kunst AE, Stadhouders PH, Tuynman HA, Poen AC, van Nieuwkerk KM, et al. Rising incidence and prevalence of primary biliary cirrhosis: a large population-based study. Liver Int. 2014;34(6):e31–8.Google Scholar
  19. 19.
    Griffiths L, Dyson JK, Jones DE. The new epidemiology of primary biliary cirrhosis. Semin Liver Dis. 2014;34(3):318–28.CrossRefPubMedGoogle Scholar
  20. 20.
    Karlsen TH, Boberg KM, Schrumpf E. Primary sclerosing cholangitis. In: Boyer TD, Manns MP, Sanyal AJ, editors. Zakim and Boyer’s hepatology: a textbook of liver disease. 6th ed. Philadelphia: Elsevier Saunders; 2012. p. 754–81.CrossRefGoogle Scholar
  21. 21.
    Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology. 2001;33(3):544–53.CrossRefPubMedGoogle Scholar
  22. 22.
    Boonstra K, Weersma RK, van Erpecum KJ, Rauws EA, Spanier BW, Poen AC, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013;58(6):2045–55.CrossRefPubMedGoogle Scholar
  23. 23.
    Karlsen TH, Schrumpf E, Boberg KM. Primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol. 2010;24(5):655–66.CrossRefPubMedGoogle Scholar
  24. 24.
    Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Loof L, Danielsson A, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol. 2002;36(3):321–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Molodecky NA, Kareemi H, Parab R, Barkema HW, Quan H, Myers RP, et al. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology. 2011;53(5):1590–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Kaplan GG, Laupland KB, Butzner D, Urbanski SJ, Lee SS. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol. 2007;102(5):1042–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Hubers LM, Maillette de Buy Wenniger LJ, Doorenspleet ME, Klarenbeek PL, Verheij J, Rauws EA, et al. IgG4-associated cholangitis: a comprehensive review. Clin Rev Allergy Immunol. 2015;48(2–3):198–206.Google Scholar
  28. 28.
    Joshi D, Webster GJ. Immunoglobulin G4-related sclerosing cholangitis. Hepatology. 2015;61(4):1432–4.CrossRefPubMedGoogle Scholar
  29. 29.
    Bjornsson E, Chari ST, Smyrk TC, Lindor K. Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature. Hepatology. 2007;45(6):1547–54.CrossRefPubMedGoogle Scholar
  30. 30.
    Mendes FD, Jorgensen R, Keach J, Katzmann JA, Smyrk T, Donlinger J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2006;101(9):2070–5.CrossRefPubMedGoogle Scholar
  31. 31.
    Fischer S, Trivedi PJ, Ward S, Greig PD, Therapondos G, Hirschfield GM. Frequency and significance of IgG4 immunohistochemical staining in liver explants from patients with primary sclerosing cholangitis. Int J Exp Pathol. 2014;95(3):209–15.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Kanno A, Nishimori I, Masamune A, Kikuta K, Hirota M, Kuriyama S, et al. Nationwide epidemiological survey of autoimmune pancreatitis in Japan. Pancreas. 2012;41(6):835–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Brito-Zeron P, Ramos-Casals M, Bosch X, Stone JH. The clinical spectrum of IgG4-related disease. Autoimmun Rev. 2014;13(12):1203–10.CrossRefPubMedGoogle Scholar
  34. 34.
    Khan SA, Emadossadaty S, Ladep NG, Thomas HC, Elliott P, Taylor-Robinson SD, et al. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? J Hepatol. 2012;56(4):848–54.CrossRefPubMedGoogle Scholar
  35. 35.
    Razumilava N, Gores GJ. Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol. 2013;11(1):13–21.Google Scholar
  36. 36.
    Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24(2):115–25.CrossRefPubMedGoogle Scholar
  37. 37.
    Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145(6):1215–29.CrossRefPubMedGoogle Scholar
  38. 38.
    Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012;61(12):1657–69.CrossRefPubMedGoogle Scholar
  39. 39.
    Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part III: liver, biliary tract, and pancreas. Gastroenterology. 2009;136(4):1134–44.CrossRefPubMedGoogle Scholar
  40. 40.
    Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB Off J Int Hepato Pancreato Biliary Assoc. 2008;10(2):77–82.CrossRefGoogle Scholar
  41. 41.
    Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology. 2005;128(6):1655–67.CrossRefPubMedGoogle Scholar
  42. 42.
    Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol. 2015;29(2):221–32.CrossRefPubMedGoogle Scholar
  43. 43.
    Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004;40(3):472–7.CrossRefPubMedGoogle Scholar
  44. 44.
    Tyson GL, Ilyas JA, Duan Z, Green LK, Younes M, El-Serag HB, et al. Secular trends in the incidence of cholangiocarcinoma in the USA and the impact of misclassification. Dig Dis Sci. 2014;59(12):3103–10.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Lepage C, Cottet V, Chauvenet M, Phelip JM, Bedenne L, Faivre J, et al. Trends in the incidence and management of biliary tract cancer: a French population-based study. J Hepatol. 2011;54(2):306–10.CrossRefPubMedGoogle Scholar
  46. 46.
    Schweitzer N, Vogel A. Systemic therapy of cholangiocarcinoma: from chemotherapy to targeted therapies. Best Pract Res Clin Gastroenterol. 2015;29(2):345–53.CrossRefPubMedGoogle Scholar
  47. 47.
    Gourgiotis S, Kocher HM, Solaini L, Yarollahi A, Tsiambas E, Salemis NS. Gallbladder cancer. Am J Surg. 2008;196(2):252–64.CrossRefPubMedGoogle Scholar
  48. 48.
    Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. Lancet Oncol. 2003;4(3):167–76.CrossRefPubMedGoogle Scholar
  49. 49.
    Kiran RP, Pokala N, Dudrick SJ. Incidence pattern and survival for gallbladder cancer over three decades – an analysis of 10301 patients. Ann Surg Oncol. 2007;14(2):827–32.CrossRefPubMedGoogle Scholar
  50. 50.
    Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer. 2006;118(7):1591–602.CrossRefPubMedGoogle Scholar
  51. 51.
    Shaffer EA. Gallstone disease: epidemiology of gallbladder stone disease. Best Pract Res Clin Gastroenterol. 2006;20(6):981–96.CrossRefPubMedGoogle Scholar
  52. 52.
    Lammert F, Sauerbruch T. Mechanisms of disease: the genetic epidemiology of gallbladder stones. Nat Clin Pract Gastroenterol Hepatol. 2005;2(9):423–33.CrossRefPubMedGoogle Scholar
  53. 53.
    Everhart JE, Khare M, Hill M, Maurer KR. Prevalence and ethnic differences in gallbladder disease in the United States. Gastroenterology. 1999;117(3):632–9.CrossRefPubMedGoogle Scholar
  54. 54.
    Russo MW, Wei JT, Thiny MT, Gangarosa LM, Brown A, Ringel Y, et al. Digestive and liver diseases statistics, 2004. Gastroenterology. 2004;126(5):1448–53.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Section for Gastroenterology, Department of Transplantation Medicine, Division of Surgery, Inflammatory Diseases and TransplantationOslo University Hospital RikshospitaletOsloNorway
  2. 2.Norwegian PSC Research Center, Department of Transplantation Medicine, Division of Surgery, Inflammatory Diseases and TransplantationOslo University Hospital RikshospitaletOsloNorway
  3. 3.Institute of Clinical Medicine, Faculty of MedicineUniversity of OsloOsloNorway

Personalised recommendations